Amycretin

Mechanism

Amycretin is a dual agonist at the amylin receptor (a complex of calcitonin receptor-like receptor [CALCRL] with receptor activity-modifying protein 1 [RAMP1]) and the calcitonin receptor (a complex of CALCRL with RAMP2/3). Amylin receptor activation promotes satiety, slows gastric emptying, and reduces postprandial glucagon — effects well established from pramlintide (an approved amylin analogue). Calcitonin receptor activation contributes to additional metabolic effects, though the precise mechanism by which dual agonism enhances weight loss beyond amylin alone is still being elucidated. The combination is hypothesised to produce synergistic anorectic and weight-reducing effects.

Evidence base

Evidence grade: Limited

The primary publicly available efficacy data for amycretin consists of a single Phase 1 trial with topline results announced by Novo Nordisk in June 2024. The sponsor reported approximately 22% mean weight loss at the highest dose over 36 weeks. This was a small, early-phase trial and results were reported via corporate press release rather than peer-reviewed publication.

Phase 2 development is underway, with trials registered on ClinicalTrials.gov. No Phase 2 or Phase 3 results have been published.

Key limitations:

• Single early-phase trial with no independent replication
• Sponsor-reported topline data (not peer-reviewed at time of writing)
• Small sample size characteristic of Phase 1
• No long-term safety data beyond the Phase 1 treatment period

Researchers should treat the 22% weight loss figure as preliminary and await peer-reviewed Phase 2/3 data before drawing conclusions about efficacy.

Protocols

No research protocols exist outside of registered clinical trials. In the Phase 1 study, amycretin was administered as a once-daily subcutaneous injection. Specific dosing details have not been fully disclosed publicly.

Any use outside of registered clinical trials is not supported by evidence. Researchers monitoring this compound should reference ClinicalTrials.gov and EudraCT for trial details as they become available.

UK legal status

Amycretin is an investigational compound with no MHRA marketing authorisation. It is not a licensed medicine in the UK. As an unlicensed research peptide, it falls into a UK grey area — it may be legal for legitimate research purposes but is not approved for human therapeutic use.

No UK-specific regulatory guidance has been issued for amycretin. General MHRA guidance on unlicensed medicines and research chemicals applies. The compound should not be marketed or sold as a medicine or supplement.

Vendor notes

Amycretin is not available from any vetted UK peptide vendor. As an investigational compound in early clinical development, it is not in commercial production. Any vendor claiming to sell amycretin should be treated with extreme caution, as the material would be of unverifiable quality and provenance.